BioNTech (BNTX) officer details options, PSUs, RSUs and shares in Form 3

Rhea-AI Filing Summary

BioNTech SE officer Ryan James Timothy Patrick filed an initial ownership report showing existing equity awards and share holdings. He holds options over 25,459 and 8,838 ordinary shares with exercise prices of EUR 75.91 and EUR 93.35 that vest annually over four years and become exercisable four years after grant, subject to performance and other conditions. He also holds 11,047 performance share units, plus restricted stock units over 740 and 750 ordinary shares that vest in equal annual installments over four years with a four-year waiting period. In addition, he directly owns 4,795 ordinary shares, including 3,990 held jointly with his spouse.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Ryan James Timothy Patrick

(Last) (First) (Middle)

C/O BIONTECH SE

AN DER GOLDGRUBE 12

(Street)

MAINZ D-55131

(City) (State) (Zip)

GERMANY

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BioNTech SE [ BNTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See remarks.

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	4,795(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	08/26/2028(2)	08/26/2034	Ordinary Shares(3)	25,459	(4)(5)	D
Option (right to buy)	05/28/2029(2)	05/28/2035	Ordinary Shares(3)	8,838	(5)(6)	D
Performance Share Unit	05/27/2029(7)	05/27/2035	Ordinary Shares(7)	11,047	$0	D
Restricted Stock Unit	12/09/2026(8)	(8)	Ordinary Shares(9)	740	(10)	D
Restricted Stock Unit	12/08/2027(8)	(8)	Ordinary Shares(9)	750	(10)	D

Explanation of Responses:

1. Includes 3,990 shares held jointly with the Reporting Person's spouse.

2. The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.

3. The option may be settled in ordinary shares, American Depositary Shares ("ADSs") and/or cash at the election of the supervisory board.

4. The exercise price of this option is EUR 75.91.

5. Subject to adjustment such that the trading price of an ADS as of an exercise date does not exceed 800% of the grant date exercise price.

6. The exercise price of this option is EUR 93.35.

7. Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

8. The restricted stock units ("RSUs") vest in equal annual installments over four years commencing on the grant date and are subject to a four-year waiting period.

9. The RSUs may be settled in ordinary shares, ADSs, and/or cash at the election of the plan administrator.

10. Each RSU represents a contingent right to receive one ordinary share, one ADS, and/or the cash equivalent thereof at the election of the plan administrator.

Remarks:

Chief Legal Officer and Chief Business Officer; Exhibit List - Exhibit 24 - Power of Attorney

	/s/ Humza Bokhari, Attorney-in-Fact	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the BioNTech (BNTX) Form 3 filing by Ryan James Timothy Patrick show?

The Form 3 shows Ryan James Timothy Patrick’s existing BioNTech equity interests, including options, performance share units, restricted stock units, and ordinary shares. It is an initial ownership report, not a record of new purchases or sales of BioNTech stock.

How many BioNTech options does Ryan James Timothy Patrick report on his Form 3?

He reports options linked to 25,459 and 8,838 BioNTech ordinary shares. These options vest annually in equal installments over four years and become exercisable four years after grant, subject to performance-based and other conditions described in the footnotes.

What performance share units are disclosed for BioNTech (BNTX) in this Form 3?

The filing lists 11,047 performance share units, each economically equivalent to one BioNTech ordinary share. Vesting occurs annually over four years and is tied to share price performance relative to the Nasdaq Biotechnology Index and continued service through the relevant dates.

What restricted stock units does Ryan James Timothy Patrick hold in BioNTech?

He holds restricted stock units over 740 and 750 BioNTech ordinary shares. These RSUs vest in equal annual installments over four years and are subject to a four-year waiting period, with settlement potentially in shares, ADSs, cash, or a combination.

How many BioNTech ordinary shares does Ryan James Timothy Patrick directly own?

The Form 3 reports direct ownership of 4,795 BioNTech ordinary shares. According to the footnotes, this figure includes 3,990 shares held jointly with his spouse, reflecting both his individual and joint holdings as of the reporting date.

Are the BioNTech equity awards in this Form 3 settled in shares or cash?

The options, performance share units, and restricted stock units may be settled in BioNTech ordinary shares, ADSs, cash, or other forms. The specific settlement form is determined at the election of the supervisory board or plan administrator, as described in the footnotes.